The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapy.
For 95 protease inhibitor-experienced HIV-1-infected patients, the genotypic inhibitory quotient (GIQ; trough level/number of mutations) was calculated for lopinavir. Three different sets of mutations showed equal predictive value. However, the use of cumulative numbers of mutations for calculation of the GIQ showed significantly better association with the virological response. Furthermore, the predictive value of the GIQ was no different from that of the number of mutations alone.
Hoefnagel
Jolanda G M
JG
Department of Medical Microbiology, Nijmegen University Centre for Infectious Diseases, the Netherlands.
van der Lee
Manon J
MJ
Koopmans
Peter P
PP
Schuurman
Rob
R
Jurriaans
Suzanne
S
van Sighem
Ard I
AI
Gras
Luuk
L
de Wolf
Frank
F
Galama
Jochem M D
JM
Burger
David M
DM
D024882:Drug Resistance, Viral / Q000235:genetics; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy / Q000235:genetics*; D017320:HIV Protease Inhibitors / Q000097:blood / Q000627:therapeutic use*; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D061466:Lopinavir; D009154:Mutation; D011744:Pyrimidinones / Q000097:blood / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014779:Virus Replication / Q000187:drug effects / Q000235:genetics
D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D061466:Lopinavir